Related Experiment Videos
Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma
L Ciarallo1, D Brousseau, S Reinert
1Department of Pediatrics, Brown University School of Medicine, Providence, RI, USA.
Insights
Intravenous magnesium sulfate significantly improved pulmonary function in pediatric patients with moderate to severe asthma exacerbations. This treatment also increased the likelihood of home discharge compared to placebo.
Area of Science:
- Pediatric Emergency Medicine
- Pulmonology
- Pharmacology
Background:
- Asthma exacerbations are a common cause of pediatric emergency department visits.
- Effective treatments for moderate to severe asthma exacerbations are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of a 40-mg/kg dose of intravenous magnesium sulfate in pediatric patients with moderate to severe asthma.
- To assess the impact of magnesium sulfate on short-term pulmonary function and discharge disposition.
Main Methods:
- A double-blind, placebo-controlled trial was conducted in two urban tertiary care pediatric emergency departments.
- Thirty pediatric patients (aged 6-17.9 years) with acute asthma exacerbations received either magnesium sulfate (40 mg/kg) or a saline placebo infusion.
Main Results:
- The magnesium sulfate group demonstrated significant short-term improvements in predicted peak expiratory flow rate, forced expiratory volume in 1 second, and forced vital capacity compared to placebo.
- These pulmonary function improvements were sustained and more pronounced at 110 minutes post-infusion.
- Patients receiving intravenous magnesium sulfate were significantly more likely to be discharged home (8/16) than those receiving placebo (0/14).
Conclusions:
- A 40-mg/kg dose of intravenous magnesium sulfate is effective in improving short-term pulmonary function in children with moderate to severe asthma exacerbations.
- Intravenous magnesium sulfate represents a promising therapeutic option for pediatric asthma emergencies, potentially reducing hospital admissions.
Objective:
To evaluate the efficacy of a 40-mg/kg dose of intravenous magnesium sulfate for moderate to severe asthma exacerbations in pediatric patients.
Study Design:
Double-blind placebo-controlled trial.
Setting:
Two urban tertiary care pediatric emergency departments.
Subjects:
Thirty patients, aged 6 to 17.9 years, being treated for an acute asthma exacerbation.
Intervention:
Eligible patients received either a magnesium sulfate infusion of 40 mg/kg or saline solution.
Results:
At 20 minutes, the time at which the infusion was completed, the magnesium group had a significantly greater percentage of absolute improvement from baseline in each of the following: predicted peak expiratory flow rate (8.6% vs 0.3%, P<. 001), forced expiratory volume in 1 second (7.0% vs 0.2%,P<.001), and forced vital capacity (7.3% vs -0.7%, P<.001). The improvement was greater at 110 minutes: peak expiratory flow rate (25.8% vs 1.9%, P<.001), forced expiratory volume in 1 second (24.1% vs 2.3%; P<. 001), and forced vital capacity (27.3% vs 2.6%, P<.001). Patients who received intravenous magnesium were more likely to be discharged to their homes than those who received the placebo (8/16 vs 0/14; P=. 002).
Conclusion:
Children treated with 40 mg/kg of intravenous magnesium sulfate for moderate to severe asthma showed remarkable improvement in short-term pulmonary function.